RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for hard-to-treat endometrial cancer
Disease control OngoingThis study tests whether adding a third drug (ribociclib) to a two-drug combination (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. The trial involves 90 participants and aims to see if the three-drug combo can shrink tumors or st…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for recurrent ovarian and endometrial cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called tazemetostat in 62 people whose ovarian or endometrial cancer has returned after previous treatment. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the drug can shrink tumors or stop them from growing f…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo therapy aims to slow advanced endometrial cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) is safer and works better than hormone therapy alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer that h…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Engineered virus targets Hard-to-Treat endometrial cancer in early trial
Disease control OngoingThis early-phase trial tests a specially designed virus (VSV-hIFNbeta-NIS) that is meant to infect and kill cancer cells while leaving healthy cells alone. It is given intravenously to people with stage IV or recurrent endometrial cancer. The main goals are to find the safest dos…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Immunotherapy plus chemo shows promise for tough endometrial cancers
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the cancer growing. About 813 participants with stage III, IV, or recurrent di…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 05, 2026 11:54 UTC